Insulet Corp. Stock
Insulet Corp. Stock
Insulet Corp. gained 2.500% today.
Insulet Corp. is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
With a target price of 215 € there is a positive potential of 29.48% for Insulet Corp. compared to the current price of 166.05 €.
Pros and Cons of Insulet Corp. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insulet Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insulet Corp. | 2.500% | -3.655% | 6.272% | -39.265% | -16.327% | -21.452% | - |
| Neogen Corp. | 1.650% | 1.653% | 8.850% | -18.000% | -32.787% | -67.632% | -51.335% |
| Bio-Rad Labs Inc. A | 0.260% | -2.647% | 1.846% | -25.450% | -9.809% | -45.738% | - |
| Merit Medical Systems | -1.320% | 0.000% | 7.971% | -0.667% | 9.559% | 51.423% | 61.325% |
Comments
Insulet Co. (NASDAQ: PODD) had its price target lowered by analysts at Raymond James from $218.00 to $213.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Jefferies Financial Group Inc. from $255.00 to $260.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet Co. (NASDAQ: PODD) had its price target lowered by analysts at Piper Sandler from $250.00 to $230.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
News
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
Hospital chain HCA Healthcare, Inc. (NYSE: HCA) has been working on a bullish base and even managed to post gains in a week when the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) pulled back.
Investors
